Gilead Sciences, Inc.

▲ Bull Case

• ◆Yeztugo reaches $8.5B FY2030 peak (top of $5–8B variant range) as injectable PrEP penetration accelerates to 25–30% of eligible US patients; EU approval H2 2026 adds $1.5B incremental; 2x/year dosing advantage proves durable vs. ViiV Apretude and delayed Merck islatravir
• ◆Bict+Lena LA combo approves August 27, 2026 (85% probability) and ramps to $5.5B FY2030 as virally suppressed patients switch from oral Biktarvy to twice-yearly maintenance; long-acting platform extends HIV franchise effective patent runway to 2039+, permanently re-rating narrative
• ◆Market re-rates GILD to 16x P/E on FY2027E EPS of $11.55 (peer-parity justified by best-in-class patent runway + franchise growth momentum) → fair value $185/share (+41% upside; +47% 2-year total return)

▼ Bear Case

• ◆Yeztugo plateaus at $4.5B FY2030 (below variant range) as oral generic Truvada at $40/month creates step-therapy barriers; payer pull-through slower than expected; sequential growth decelerates from +72% Q1 2026 to <20% within 4 quarters; PrEP penetration reaches only 15% of eligible US patients
• ◆AstraZeneca's Dato-DXd captures NSCLC and TNBC dominance; Trodelvy peak compressed to $1.5B vs. $2.6B base case; Immunomedics goodwill becomes impairment candidate by FY2028; oncology growth pillar evaporates as credible second revenue engine
• ◆IRA Medicare Biktarvy negotiation lands at $1.0B+/yr impact with 30%+ net price reduction implemented FY2028; combined with formulary step-therapy, US HIV treatment net realized prices compress 12–15%; multiple compresses to 13x → fair value $110/share (−16% downside; −10% 2-year total return even with dividend)

“The core debate is whether the Yeztugo + LA combo HIV franchise expansion is enough to durably re-rate GILD to peer-parity multiples (15–16x), or whether Medicare IRA negotiation + the eventual Biktarvy 2036 loss of exclusivity keep the discount permanent at 13–14x. Bulls argue GILD has the best patent runway in large-cap pharma (2036 Biktarvy + 2039 Yeztugo/lenacapavir), the strongest HIV moat in pharmaceutical history, and that Yeztugo launch is generating earnings revisions that consensus has yet to absorb—GILD should trade at parity with ABBV given equal/better patent runway. Bears argue GILD remains too HIV-concentrated (~67% of revenue), is structurally exposed to IRA negotiation (Biktarvy eligible 2027, impact 2028+), and even at $130 (14x) the stock is fairly valued, not undervalued—the prior '10x P/E variant' has been substantially captured and we are now in fair-value convergence phase.”

• ◆Q2 2026 earnings (late July 2026): Yeztugo sequential trajectory confirms variant or signals plateau; bull if >$1.1B, bear if <$0.9B; triggers consensus revision cycle
• ◆Bict+Lena LA combo PDUFA decision (August 27, 2026): 85% approval probability adds ~$4B FY2030 revenue and extends patent protection narrative to 2039+; 15% rejection results in 5–10% stock decline on pipeline disappointment
• ◆Yeztugo EU approval (H2 2026): >90% probability; adds €1.5B incremental peak revenue from European patients; timing critical for FY2027 growth acceleration
• ◆CMS IRA drug selection announcement (late 2026 / Q1 2027): 55% bear scenario (Biktarvy selected, triggers FY2028+ negotiation); 45% bull scenario (Biktarvy excluded, bear narrative collapses)
• ◆Trodelvy NSCLC EVOKE-03 Phase 3 data (2027): binary outcome; approval adds $1B+ peak revenue; failure caps franchise at $1.5B and evaporates oncology growth pillar

• ◆IRA Medicare Biktarvy negotiation, harsh outcome ($1.0B+/yr impact): moderate probability (30%); high severity; triggers FY2028+ earnings compression and multiple reset to 12–13x
• ◆Yeztugo trajectory normalization < expected (plateau $4.5B FY2030 vs. $5–8B variant): moderate probability (30%); medium-high severity; delays earnings revision cycle and re-rating by 12+ months
• ◆AstraZeneca Dato-DXd dominance in NSCLC + TNBC: moderate probability (40%); medium severity; caps Trodelvy peak at $1.5B and evaporates oncology as credible growth pillar
• ◆Bict+Lena LA combo rejected by FDA: low probability (15%); medium severity; narrative damage and pipeline credibility hit; stock declines 5–10% on news; switches GILD to 'HIV-only' thesis
• ◆Value-destructive large acquisition (>$15B): low probability (10%); high severity; capital allocation discipline broken; magrolimab/Immunomedics repeat risk; goodwill impairment exposure